CN106983151A - A kind of inflammatory bowel disease tailored version clinical nutrition formula and preparation method thereof - Google Patents
A kind of inflammatory bowel disease tailored version clinical nutrition formula and preparation method thereof Download PDFInfo
- Publication number
- CN106983151A CN106983151A CN201710198925.5A CN201710198925A CN106983151A CN 106983151 A CN106983151 A CN 106983151A CN 201710198925 A CN201710198925 A CN 201710198925A CN 106983151 A CN106983151 A CN 106983151A
- Authority
- CN
- China
- Prior art keywords
- powder
- inflammatory bowel
- vitamin
- bowel disease
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 62
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 47
- 230000035764 nutrition Effects 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 238000009472 formulation Methods 0.000 title abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 109
- 239000011782 vitamin Substances 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 235000012054 meals Nutrition 0.000 claims abstract description 37
- 229940088594 vitamin Drugs 0.000 claims abstract description 33
- 229930003231 vitamin Natural products 0.000 claims abstract description 33
- 235000013343 vitamin Nutrition 0.000 claims abstract description 33
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 33
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 32
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 28
- 230000035622 drinking Effects 0.000 claims abstract description 27
- 235000008216 herbs Nutrition 0.000 claims abstract description 27
- 230000010354 integration Effects 0.000 claims abstract description 27
- 235000013305 food Nutrition 0.000 claims abstract description 21
- 241000196324 Embryophyta Species 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 17
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 15
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 15
- 239000011573 trace mineral Substances 0.000 claims abstract description 15
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 15
- 241000234435 Lilium Species 0.000 claims abstract description 14
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 13
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 13
- 150000001413 amino acids Chemical class 0.000 claims abstract description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 13
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 11
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 11
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 11
- 244000197580 Poria cocos Species 0.000 claims abstract description 11
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 11
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 11
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 11
- 235000015097 nutrients Nutrition 0.000 claims abstract description 10
- 244000062793 Sorghum vulgare Species 0.000 claims abstract description 9
- 238000004108 freeze drying Methods 0.000 claims abstract description 9
- 235000019713 millet Nutrition 0.000 claims abstract description 9
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 4
- 238000003809 water extraction Methods 0.000 claims abstract description 3
- 244000235659 Rubus idaeus Species 0.000 claims abstract 3
- 235000013350 formula milk Nutrition 0.000 claims description 27
- 235000018102 proteins Nutrition 0.000 claims description 27
- 235000019197 fats Nutrition 0.000 claims description 21
- 239000002994 raw material Substances 0.000 claims description 17
- 235000014633 carbohydrates Nutrition 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 235000000346 sugar Nutrition 0.000 claims description 9
- 241000206575 Chondrus crispus Species 0.000 claims description 8
- 235000010489 acacia gum Nutrition 0.000 claims description 8
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000000835 fiber Substances 0.000 claims description 6
- 235000013373 food additive Nutrition 0.000 claims description 6
- 239000002778 food additive Substances 0.000 claims description 6
- 235000003132 food thickener Nutrition 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 229920001285 xanthan gum Polymers 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 108010011485 Aspartame Proteins 0.000 claims description 4
- 229920002752 Konjac Polymers 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 239000000605 aspartame Substances 0.000 claims description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 4
- 235000010357 aspartame Nutrition 0.000 claims description 4
- 229960003438 aspartame Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 235000013599 spices Nutrition 0.000 claims description 4
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 3
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 3
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 3
- 229920002581 Glucomannan Polymers 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 229920000161 Locust bean gum Polymers 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 229940046240 glucomannan Drugs 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 239000000252 konjac Substances 0.000 claims description 3
- 235000010485 konjac Nutrition 0.000 claims description 3
- 235000010420 locust bean gum Nutrition 0.000 claims description 3
- 239000000711 locust bean gum Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000003925 fat Substances 0.000 claims description 2
- 235000020214 lactose-free milk formula Nutrition 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000011805 ball Substances 0.000 claims 1
- 239000010977 jade Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 abstract description 12
- 208000024891 symptom Diseases 0.000 abstract description 8
- 210000003743 erythrocyte Anatomy 0.000 abstract description 6
- 108010074051 C-Reactive Protein Proteins 0.000 abstract description 5
- 102100032752 C-reactive protein Human genes 0.000 abstract description 5
- 238000004062 sedimentation Methods 0.000 abstract description 5
- 230000003870 intestinal permeability Effects 0.000 abstract description 4
- 235000010469 Glycine max Nutrition 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000000463 material Substances 0.000 description 16
- 208000011231 Crohn disease Diseases 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 244000068988 Glycine max Species 0.000 description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 240000007651 Rubus glaucus Species 0.000 description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 12
- 229920001503 Glucan Polymers 0.000 description 11
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 11
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
- 229920002774 Maltodextrin Polymers 0.000 description 10
- 239000005913 Maltodextrin Substances 0.000 description 10
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 10
- 229940035034 maltodextrin Drugs 0.000 description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- -1 lard Substances 0.000 description 9
- 239000011715 vitamin B12 Substances 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 229920001202 Inulin Polymers 0.000 description 8
- 240000008866 Ziziphus nummularia Species 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 8
- 229940029339 inulin Drugs 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 241000251468 Actinopterygii Species 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229960005069 calcium Drugs 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 235000019688 fish Nutrition 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- 229960003284 iron Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 6
- 108010038807 Oligopeptides Proteins 0.000 description 6
- 102000015636 Oligopeptides Human genes 0.000 description 6
- 235000004347 Perilla Nutrition 0.000 description 6
- 244000124853 Perilla frutescens Species 0.000 description 6
- 229930003316 Vitamin D Natural products 0.000 description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000003240 coconut oil Substances 0.000 description 6
- 235000019864 coconut oil Nutrition 0.000 description 6
- 229960000304 folic acid Drugs 0.000 description 6
- 235000019152 folic acid Nutrition 0.000 description 6
- 239000011724 folic acid Substances 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 239000004006 olive oil Substances 0.000 description 6
- 235000008390 olive oil Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 150000004666 short chain fatty acids Chemical class 0.000 description 6
- 235000021391 short chain fatty acids Nutrition 0.000 description 6
- 239000003549 soybean oil Substances 0.000 description 6
- 235000012424 soybean oil Nutrition 0.000 description 6
- 235000019166 vitamin D Nutrition 0.000 description 6
- 239000011710 vitamin D Substances 0.000 description 6
- 150000003710 vitamin D derivatives Chemical class 0.000 description 6
- 229940046008 vitamin d Drugs 0.000 description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 5
- 240000003183 Manihot esculenta Species 0.000 description 5
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 5
- 244000046052 Phaseolus vulgaris Species 0.000 description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 5
- 229930003270 Vitamin B Natural products 0.000 description 5
- 229930003427 Vitamin E Natural products 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 235000013734 beta-carotene Nutrition 0.000 description 5
- 239000011648 beta-carotene Substances 0.000 description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 5
- 229960002747 betacarotene Drugs 0.000 description 5
- 235000021277 colostrum Nutrition 0.000 description 5
- 210000003022 colostrum Anatomy 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000009266 disease activity Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 5
- 150000003271 galactooligosaccharides Chemical class 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 239000004519 grease Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000003301 hydrolyzing effect Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 210000004347 intestinal mucosa Anatomy 0.000 description 5
- 229960003512 nicotinic acid Drugs 0.000 description 5
- 235000001968 nicotinic acid Nutrition 0.000 description 5
- 239000011664 nicotinic acid Substances 0.000 description 5
- 229940055726 pantothenic acid Drugs 0.000 description 5
- 235000019161 pantothenic acid Nutrition 0.000 description 5
- 239000011713 pantothenic acid Substances 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 229960003080 taurine Drugs 0.000 description 5
- 235000019155 vitamin A Nutrition 0.000 description 5
- 239000011719 vitamin A Substances 0.000 description 5
- 235000019156 vitamin B Nutrition 0.000 description 5
- 239000011720 vitamin B Substances 0.000 description 5
- 239000011716 vitamin B2 Substances 0.000 description 5
- 239000011726 vitamin B6 Substances 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- 229940045997 vitamin a Drugs 0.000 description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 244000205754 Colocasia esculenta Species 0.000 description 4
- 235000006481 Colocasia esculenta Nutrition 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 239000005862 Whey Substances 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000011162 core material Substances 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 4
- 210000003405 ileum Anatomy 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 229940091250 magnesium supplement Drugs 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 229960004203 carnitine Drugs 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 3
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 3
- 235000008718 isoliquiritigenin Nutrition 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 235000000824 malnutrition Nutrition 0.000 description 3
- 230000001071 malnutrition Effects 0.000 description 3
- 230000004682 mucosal barrier function Effects 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000011435 rock Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 235000019710 soybean protein Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SUEPNLVSSRHTSZ-WOYAITHZSA-N (2s)-2-amino-4-methylsulfanylbutanoic acid;(2s)-2-amino-4-sulfanylbutanoic acid Chemical group OC(=O)[C@@H](N)CCS.CSCC[C@H](N)C(O)=O SUEPNLVSSRHTSZ-WOYAITHZSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016880 Folate deficiency Diseases 0.000 description 2
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000034767 Hypoproteinaemia Diseases 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- 206010025476 Malabsorption Diseases 0.000 description 2
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 235000021068 Western diet Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 208000021735 chronic enteritis Diseases 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000008944 intestinal immunity Effects 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 235000003715 nutritional status Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 101710130006 Beta-glucanase Proteins 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 241000371652 Curvularia clavata Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 240000005717 Dioscorea alata Species 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 208000008081 Intestinal Fistula Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 1
- 240000001740 Momordica dioica Species 0.000 description 1
- 235000018365 Momordica dioica Nutrition 0.000 description 1
- 244000179886 Moringa oleifera Species 0.000 description 1
- 235000011347 Moringa oleifera Nutrition 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- NBSRUZQXRUNPNY-FOCLMDBBSA-N NS(=O)(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O Chemical compound NS(=O)(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O NBSRUZQXRUNPNY-FOCLMDBBSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 241001300674 Plukenetia volubilis Species 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 241000287420 Pyrus x nivalis Species 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039921 Selenium deficiency Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 235000020243 first infant milk formula Nutrition 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003626 gastrointestinal polypeptide Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical group [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 108010002060 leukoregulin Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 239000011683 manganese gluconate Substances 0.000 description 1
- 235000014012 manganese gluconate Nutrition 0.000 description 1
- 229940072543 manganese gluconate Drugs 0.000 description 1
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229950008351 salazosulfamide Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of inflammatory bowel disease tailored version clinical nutrition formula, including protein and amino acid, peptides, fat, carbohydrate, dietary fiber, macroelement, trace element, vitamin, meals elite, integration of drinking and medicinal herbs composition, natural plants compound and new resource food;Wherein meals elite includes millet powder, oatmeal, apple powder;Integration of drinking and medicinal herbs composition includes lily, peppermint, radix glycyrrhizae, Poria cocos, raspberry, matrimony vine, sealwort, jujube;Its preparation method is:Each component is previously prepared into powder, and well mixed corresponding formulation is made;Powder is made in integration of drinking and medicinal herbs composition water extraction concentration, freeze-drying, and vitamin and fat are handled by microencapsulation is made powder, and powder is made using freeze-drying in meals elite.Compared with prior art, nutrient formulation of the present invention can be energy, critical nutrients and the essential trace element needed for patients with inflammatory bowel is provided, and improve erythrocyte sedimentation rate, c reactive protein and the intestinal permeability symptom of patient.
Description
Technical field
The present invention relates to enteral nutrition preparation field, and in particular to a kind of inflammatory bowel disease tailored version clinical nutrition formula and its
Preparation method.
Background technology
Inflammatory bowel disease is the non specific chronic inflammatory process for betiding enteron aisle, including Crohn disease (CD) and ulcer
Property colitis (UC).Extensively, symptom of digestive tract weight, Relapse rate, the course of disease is long for inflammatory bowel disease extent of disease, and metabolism in addition changes,
Easily occur malnutritive.Inflammatory bowel disease patient in first visit more than with malnutrition, and disease progression, medicine or operation are controlled
Treatment has then more aggravated dystrophia, pretends the treatment means for inflammatory bowel disease, nutritional support and medicine, operation etc. are of equal importance,
And through in the whole therapeutic process of inflammatory bowel disease.
Inflammatory bowel disease (IBD) patient occur together malnutrition 20%~85% is accounted in inpatient.Different IBD lesion
Position is different, and UC lesions are limited to colon, and CD can occur in intestines and stomach all sites, especially Small bowel involvement, and influence is digested and assimilated
Function, thus CD nutritions are bad more conventional compared with UC.In CD inpatients, the malnutrition that occurs together accounts for 50%~70%,
Dietetic patient is up to 86.4% in CD inpatients in surgical department.
There is Body weight loss, Hypoproteinemia in IBD acute stages, up to 73% patient, (outstanding with inflammatory bowel disease and vitamin
It is vitamin D and vitamin B12) and microelement deficiencies, complication rate and case fatality rate rise.Under-weight in patient CD
Person is up to 65%~75%, higher than patient UC (18%~62%).Hypoproteinemia person accounts for 25%~80%, UC patients in patient CD
In account for 25%~50%.Childhood patient IBD there is 40% growth retardation occur, clinical manifestation is that body weight increase is not enough, battalion
Support bad sexual development obstacle.
IBD is agnogenic Chronic immune dysfunction.Diet is probably that pathology starts factor, particularly high sugar, height
The western diet of fat, it may be possible to increase one of startup reason of the IBD incidences of disease.In recent years, western diet and amount of exercise are reduced
Make obesity or overweight patient's IBD increasing day by day, particularly children.Recent research indicate that, in children patient IBD obesity or
Super severe one, which is accounted for, accounts for 20% in 23.6%, CD.IBD pathomechanism includes host immune status, intestinal microecology and extraneous ring
A series of changes in border (including diet and tobacco), show as systemic inflammatory response, digestion and the malabsorption of chronic states, after
Person is more more common in the patient of SBR or the history of operation that changes its course.Inflammatory factor in disease activity phase body increases, including tumour is bad
Necrosis factor α etc..
Patient IBD is bad due to digesting and assimilating, and energy expenditure increase, intestines and stomach protein loss causes energy, albumen
Matter, magnanimity and micronutrient, electrolyte and vitamin etc. lack, and its clinical characters has:1. patient IBD loses blood and iron lacks
It is weary, cause 36%~90% inflammatory bowel disease occur, influence quality of life, childhood IBD also therefore there is cognitive ability reduction.②
Vitamin B12The factor, which absorbs, needs complete ileum, therefore the vitamin B in patient CD12Deficient patients account for 20%, distal ileitis
Up to 48% in patient, ileal resection>100cm patient is up to 100%.Vitamin B12It is homocysteine-methionine generation
Thank the required common factor of approach, plasma vitamin B12It is the independent risk factor of Homocysteine that level is low.3. end
Ileum inflammation or excision cause liposoluble vitamin (A, D, E, K) and bile salt malabsorption with lacking.Also there is β in patient IBD
Carrotene and ascorbic shortage.4. there is calcium deficiency in 13%CD and 10%UC patients, and this is that ileum lesion or excision cause
Enteric cavity absorption area is not enough, and vitamin D, which absorbs, to be reduced, calcium with non-absorbent aliphatic acid be combined and dietary restriction caused by.Calcium
Bone loss, osteoporosis are IBD common nutritional complication caused by lacking;Such as patient applies glucocorticoid simultaneously, then bone
The incidence of disease lacked with osteoporosis increases respectively to 51%~77% and 17%~28%.5. IBD medicines (Salazosulfamide
Pyridine, amethopterin etc.) enteron aisle competition cause 20%~60% patient to there is folic acid deficiency, aggravate inflammatory bowel disease.Folic acid is also
The required common factor of homocysteine-methionine metabolic pathway, folic acid deficiency causes Homocysteine, as CD and
One of the reason for patient's UC thromboembolic events increase.6. chronic diarrhea causes hypomagnesemia.7. the zinc deficiency meeting that patient IBD is present
Wound healing is influenceed, may be related to chronic intestinal fistula.8. in IBD inflammation to the early carcinomatous change stage, selenium deficiency acts on preceding apoptosis
Gene, p53, NF- κ B and stress signal path expression etc..
In the nutrition treatment of inflammatory bowel disease patient, enteral nutrition (enteral nutrition, EN) is occupied importantly
Position, EN can not only improve the nutritional status of patient, can also alleviate acute attack symptom, extend disease-free period.EN can directly subtract
Light CD inflammatory activities, being embodied in the erythrocyte sedimentation rate, c reactive protein and intestinal permeability of patient is all improved.In addition, EN
To safeguarding that growth, propagation and the mucosal barrier function of intestinal mucosa have special role.Although current hormone is to adult's CD inducer remissions
Rate is higher than EN, and short compared with EN the time required to inducer remission, but is due to that hormone is restricted in clinical practice and with tight
The side effect of weight, makes EN be used widely when treating adult acute phase CD as a kind of alternative measure of hormone.Battalion
Support and support to improve nutrition situation, the unique advantage with nutrition treatment while inducer remission.And current pole on the market
The rare special nutritional formula for inflammatory bowel disease patient.
The content of the invention
It is an object of the invention to overcome defect of the prior art to match somebody with somebody there is provided a kind of inflammatory bowel disease tailored version clinical nutrition
Side and preparation method thereof, it provides science, comprehensive clinical nutrition formula, and preparation method for inflammatory bowel disease patient first
It is advanced.Inflammatory bowel disease tailored version clinical nutrition formula prepared by the present invention provides science, comprehensively clinic for patients with inflammatory bowel
Nutritional support;On the basis of the basal energy and nutrient of needed by human body are provided, moreover it is possible to mitigate the inflammatory activities of inflammatory bowel disease,
Being embodied in the erythrocyte sedimentation rate, c reactive protein and intestinal permeability of patient is all improved;In addition, addition is to safeguarding intestinal mucosa
Growth, propagation and mucosal barrier function have the integration of drinking and medicinal herbs composition of special role, natural plants compound and new resources food
Product, help to extend the paracmasis, reduce recurrence rate, reduce permanent intestines stoma ratio.
To achieve the above object, the present invention is adopted the following technical scheme that:
On the one hand, the present invention provides a kind of inflammatory bowel disease tailored version clinical nutrition formula, including following component:Protein and
Amino acid, peptides, fat, carbohydrate, dietary fiber, macroelement, trace element, vitamin, meals elite, medicine food are same
Derived components, natural plants compound and new resource food;Wherein, the meals elite includes millet powder, oatmeal, apple
Fruit powder;Wherein, the integration of drinking and medicinal herbs composition includes lily, peppermint, radix glycyrrhizae, Poria cocos, raspberry, matrimony vine, sealwort, jujube.
In order to further optimize above-mentioned technical proposal, the technical measures that the present invention is taken also include:
Preferably, the inflammatory bowel disease tailored version clinical nutrition formula, in addition to food thickening agent and food additives, institute
Food thickening agent is stated in guar gum, xanthans, locust bean gum, konjac glucomannan, pectin, carragheen, agar, gelatin, Arabic gum
At least one, the food additives are at least one of Aspartame, flavoring essence spices, brown sugar.
Preferably, the good protein that the protein and amino acid are provided accounts for gross protein and reaches more than 70%.
Preferably, the peptides account for gross protein and reach more than 2%.
Preferably, n-6 aliphatic acid in the fat:N-3 aliphatic acid=3~4:1, medium chain triglyceride accounts for total lipid content
30%~50%.
Preferably, the carbohydrate is without lactose, using lactose-free formula.
Preferably, the dietary fiber is water-soluble dietary fiber, using low fiber prescription.
Preferably, the parts by weight of the component are:20~40 parts of protein and amino acid, 1~3 part of peptides, fat 5~
20 parts, 20~60 parts of carbohydrate, 1~3 part of dietary fiber, 0.6~1.2 part of macroelement, trace element 0.01-0.06
Part, 0.05~0.25 part of vitamin, 0.2~1 part of meals elite, 0.1~6 part of integration of drinking and medicinal herbs composition, natural plants compound
0.1-1 parts and 0.02-0.2 parts of new resource food.
Preferably, the parts by weight of each component are as follows in the integration of drinking and medicinal herbs composition:It is 0-1 parts of lily, 0-1 parts of peppermint, sweet
Careless 0-1 parts, 0-1 parts of Poria cocos, 0-1 parts of raspberry, 0-1 parts of matrimony vine, 0-1 parts of sealwort, 0-1 parts of jujube.
Preferably, the protein is selected from hydrolyzing lactoalbumin powder, soy bean protein hydrolysate, whole milk powder, dried whole-egg, newborn iron
At least one of albumen, bovine colostrum, protein peptides;The amino acid is selected from 1B-Pidolidone, Pidolidone, L-
At least one of arginine, L-Trp, Glu, taurine, Valine, ILE, L-Leu;Its
In, the protein peptides are selected from soybean oligopeptide, wheat protein peptide, pupa albumen peptide, ocean fish oligopeptide powder, laughable peptide, amino
At least one of peptide, ovalbumin peptide.
Preferably, the fat includes saturated fatty acid, polyunsaturated fatty acid, monounsaturated fatty acids, OPO structures
At least one of fat, DHA, EPA, ARA, phosphatide, more specifically it is described fat include safflower seed oil, walnut oil, peanut oil,
Soybean oil, Ah's glycerine, olive oil, tea oil, oil and fat of sacha inchi, coconut oil, perilla herb oil, deep sea fish oil, cupu oil, palm oil, butter,
Cream, lard, medium chain triglyceride, lecithin, single diglycerine fatty acid ester.
Preferably, the carbohydrate include fructose, rock sugar, glucose, maltodextrin, tapioca, cornstarch,
At least two in resistant starch.
Preferably, the dietary fiber is water-soluble dietary fiber and insoluble dietary fiber, and it includes inulin, konjaku
In powder, galactooligosaccharide, FOS, oligoisomaltose, soybean polyoses, cyclodextrin, resistant dextrin, soybean fiber at least
It is a kind of.
Preferably, the macroelement is selected from calcium citrate, L-calcium lactate, calcium monohydrogen phosphate, K-IAO, sodium citrate
At least one of with magnesium gluconate.
Preferably, the trace element is selected from ferrous gluconate, KI, zinc gluconate, sodium selenite, glucose
At least one of sour copper, chromium sulfate, manganese gluconate and sodium molybdate.
Preferably, the liposoluble vitamin is selected from vitamin A, beta carotene, vitamin D3, vitamin E, vitamin K1
At least one of.
Preferably, the water soluble vitamin is selected from vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin
At least one of C, pantothenic acid, folic acid, nicotinic acid, choline, inositol, biotin.
Preferably, the meals elite is selected from cereal, beans, potato class, greengrocery, Homonemeae, nut-seed class, fishes and shrimps
At least one of class, poultry meat, fruits;Wherein described cereal it is main by rice meal, millet powder, black rice flour, coixlacrymajobi powder,
One kind in corn flour, wheat germ powder, oatmeal, buckwheat or at least two compositions, the beans it is main by peameal, it is green
One kind or at least two compositions in bean powder, black bean powder, red bean powder, soy meal, the potato class is mainly made up of common yam rhizome powder, described
Vegetable powder is main by one in carrot meal, white radish powder, pumpkin powder, spinach powder, tomato meal, broccoli powder, balsam pear powder, cucumber powder
Plant or several compositions, the Homonemeae is main by the one or more in mushroom powder and white fungus powder, and the nut-seed class is main
It is lotus nut starch, the fish and shrimp are mainly made up of the one or more in salmon powder and cod meal, the poultry meat master
If being made up of the one or more in chicken meal, powdered beef, the fruits are main by red date powder, longan powder, apple powder, cherry
One or more of compositions in peach powder, citrus powder, pyrus nivalis powder;The preferred millet powder of meals elite, oatmeal, apple powder.
Preferably, the natural plants compound is selected from l-cn, Glucosamine, FOS, lutein, plant
At least one of sterol, lycopene, resveratrol, allicin;The natural plants compound is preferably l-cn.
Preferably, the new resource food is selected from first milk basic protein, γ-aminobutyric acid, chitosan oligosaccharide, eucommia Bark male flower, freshwater mussel
In meat polysaccharide, bamboo-leaves flavones, CPP, avenabeta glucosan, yeast beta-dextran, leaf of Moringa, xylo-oligosaccharide extremely
Few one kind;The new resource food is preferably avenabeta glucosan.
On the other hand, the present invention relates to a kind of preparation method of above-mentioned inflammatory bowel disease tailored version clinical nutrition formula, including
Following steps:
Step 1: by the protein and amino acid of predetermined weight number, peptides, fat, carbohydrate, dietary fiber,
Macroelement, trace element, vitamin, integration of drinking and medicinal herbs composition, natural plants compound and new resource food are prepared into respectively
Particle diameter is 150~250 μm of powder;
It is well mixed Step 2: powder prepared by the step one is poured into cone-type mixer successively;
Step 3: using the step one be well mixed powder be prepared into nutrient powder, nutrition emulsion, capsule, tablet,
At least one of pill or oral liquid;
Wherein, the raw material of the integration of drinking and medicinal herbs composition is crushed, water extraction is concentrated, and concentrate is carried out into freeze-drying system
Into integration of drinking and medicinal herbs component powders;
Wherein, the vitamin and fat are handled by microencapsulation respectively is prepared into vitamin powder and fat powder;
Wherein, the meals elite is prepared into meals elite powder using freeze drying process.
Preferably, the preparation process of the integration of drinking and medicinal herbs component powders is as follows:Using pulverizer to predetermined weight number
Raw material is crushed, and the raw material of crushing is placed in container, is added 3~8 times of the water that weight is raw material weight, is carried out immersion 3
~4 hours, then soak is carried out to decoct 30~60min, filtering removes raw material, leaves and takes decoction liquor, carries out decoction liquor dense
Contracting, freeze-drying, then sieving prepare integration of drinking and medicinal herbs component powders.
Preferably, what the microencapsulation of the vitamin was handled comprises the following steps that:1) it regard liposoluble vitamin as core
Material, from sodium carboxymethylcellulose, gelatin, carragheen, xanthans, Arabic gum, maltodextrin, lipoprotein, corn syrup, big
Beans protein isolate, whole-fat milk powder, dietary fiber, inulin, PURE WHEY, oligoisomaltose, soybean fiber, lactose, rock sugar
One or more in powder, emulsifying agent, stabilizer are as wall material, high-pressure homogeneous emulsification, and spraying is instantaneous to be dried, and screening prepares liposoluble
Property vitamin powder;2) using water soluble vitamin as core, from sodium carboxymethylcellulose, gelatin, carragheen, xanthans,
Arabic gum, maltodextrin, lipoprotein, corn syrup, soybean protein isolate, whole-fat milk powder, dietary fiber, inulin, whey egg
One or more in white powder, oligoisomaltose, soybean fiber, lactose, candy sugar powder, emulsifying agent, stabilizer are mixed as wall material
Close uniform, spraying is instantaneous to be dried, and screening prepares water soluble vitamin powder.
Preferably, the specific implementation step of the fatty micro-capsule embedding techniques is as follows:By fat, emulsifying agent, wall material with
Water mixed dissolution prepares emulsion;After the stirring mixing of above-mentioned emulsion, emulsifying homogeneous processing is carried out, spraying is then carried out dry
Dry, screening prepares powdered oil, and powdered oil is compared with conventional grease, and its dispersiveness, water solubility, emulsibility, inoxidizability are all
Improve a lot;Wherein, the emulsifying agent be selected from fatty acid glyceride (glyceride), methyl glycol fatty acid ester (propylene glycol ester),
One or more in sorbitan aliphatic ester (sorbitan acid), sucrose fatty ester (sucrose ester), lecithin;The wall
Material is selected from sodium carboxymethylcellulose, gelatin, carragheen, xanthans, Arabic gum, maltodextrin, lipoprotein, corn syrup, big
Beans protein isolate, whole-fat milk powder, dietary fiber, inulin, PURE WHEY, oligoisomaltose, soybean fiber, lactose, rock sugar
One or more in powder, emulsifying agent, stabilizer.
Preferably, the freeze drying process of the meals elite is comprised the following steps that:Choose raw material and smashed to pieces juxtaposition
Enter in refrigerator and freezed, the raw material after freezing are placed in into heating in sealed vacuum tank dehydrates it, described
Then the vacuum degree control of vacuum tank is heated to material temperature be solved below the maximum temperature of its permission in 10-30Pa
Drying is analysed, the time dehydrated is 1~2h, and the time of the parsing-desiccation is 4~6h, and the raw material for drying completion is entered
The ground sieve of row is prepared into meals elite powder.
The present invention eats same using with the medicine for having special role to safeguarding growth, propagation and the mucosal barrier function of intestinal mucosa
Derived components, it includes lily, peppermint, radix glycyrrhizae, Poria cocos, raspberry, matrimony vine, sealwort, jujube.
Lily can raise peripheral leukocytes, and be improved the effect of immunity of organisms, and lily gavage can prevent endoxan
Caused animal leukopenia;Colchicin contained by lily can suppress the propagation of cell, and with resist oxygen lack with it is antifatigue
Effect;Water-soluble polysaccharide contained by lily can promote Immune Function.
Active ingredient peppermint oil and its main component menthol in peppermint is to the rabbit under ex vivo situation, guinea pig ileum
The tension force of activity, intensity, intensity-Tension Difference have obvious inhibitory action, and antihistamine, acetylcholine, barium chloride etc. can be drawn
The intestinal tube activity risen is hyperfunction.
Radix glycyrrhizae can reduce intestinal tube tensity, reduce shrinkage amplitude, the isoliquiritigenin contained by it to carbachol, potassium chloride,
The mouse jejunum of barium chloride induction, which shrinks, strong spasmolysis, and the mechanism of action of radix glycyrrhizae spasmolysis is probably that isoliquiritigenin can be non-competing
Suppress to striving property contraction caused by acetylcholine, while isoliquiritigenin is a kind of aldose reductase inhibitor, by suppressing epoxy
Synthase, LOX, the activity of peroxidase carry out anti-platelet aggregation, play antiinflammatory action;Radix Glycyrrhizae total saponins contained by it
With direct antiinflammatory action, its antiinflammatory action is with reducing the generation of Macrophage Inflamatory medium and discharging, suppress arachidonic acid generation
The key enzyme for thanking to approach PGE2 synthesis is closely related;Glycyrrhizin contained by it can improve the threshold of pain of mouse in mouse hot-plate experiment
Value, reduces mouse writhing number of times in acetic acid twisting experiment, and paraxylene causes mice auricle swelling to have obvious inhibitory action.
Active ingredient pachymaran body in Poria cocos has the effect of enhancing immunologic function, and it has anti-atrophy of thymus gland and anti-
The function that spleen increases and tumor suppression grows;Carboxymethylpachymaran have immunological regulation, protecting liver, lowering enzymes, indirectly it is antiviral, induce
With Stimulation effect interferon, mitigate radiation side reaction, induce with a variety of physiologically actives such as Stimulation effect leukoregulin, without bad poison
Side effect;Pachymaran truly has and pointedly protects immune organ, increases cellular immune function, so as to improve body condition, increases
Plus anti-infection ability, especially there is strong effect to old human immunity function.
Contained hippuric acid can change the pH-value of enteron aisle and the pH-value of the urinary tract in raspberry, meanwhile, in raspberry
Tannic acid energy antistaphylohemolysin, salmonella and Escherichia coli, strengthen human immunity force;Ellagic acid in raspberry can be supported
Many chemical carcinogens such as anti-polycyclic aromatic hydrocarbon, nitrosamine, mycotoxin and aflatoxins, can protect people to show consideration for
Body tissue, strengthens body function;In raspberry contain natural aspirin (i.e. salicylic acid), can Antipyretic, anticoagulant, also may be used
Reduce the incidence of cardiovascular and cerebrovascular embolism;Contain substantial amounts of anthocyanidin in raspberry, it is the clear of efficient resisting oxidation free radical
Except agent, with powerful antioxidation activity.
Active ingredient LBP-X in matrimony vine can strengthen mice spleen lymphocytes proliferation reaction, be used in combination LBP and
ConA has synergy;Matrimony vine contains the human body essential nutrient element such as abundant carrotene, vitamin and calcium, iron, and matrimony vine has
The effect clear liver and improved vision, it can also improve immunity of organisms, regulation blood glucose blood pressure, promote gastrointestinal peristalsis, and it is also to hematopoiesis function
There is facilitation.
Sealwort, which has, improves CY induced mice marrow hemopoiesis functions, increases leucocyte and red blood cell number, is incarnadined marrow more
Cell (PCE) micronuclear rates (MNR) declines (P < 0.01), can improve mouse peritoneal macrophage function.
Active ingredient date polysaccharide in jujube can significantly improve the phagocytic function of internal mononuclear phagocyte system;Jujube
Thick many candies, neutral polysaccharide and acidic polysaccharose can promote the propagation of lymphocyte, and neutral polysaccharide is to lymphocyte proliferation
Facilitation is stronger than the facilitation of acidic polysaccharose.
The water-soluble dietary fiber of the present invention also addition 65~75%, water-soluble dietary fiber can be by intestinal flora metabolism ferment
Solve as a variety of short chain fatty acids, including acetic acid, propionic acid, butyric acid etc., short chain fatty acids are the significant energies of gastrointestinal tract epithelial cell
Material, short chain fatty acids make intestinal epithelial cell have more preferable nutritional status, reduce noxious material and Inflammatory substances glutinous by intestines
Film enters circulation;Short chain fatty acids also promote gastrointestinal tract epithelial cell to secrete mucin and gastrointestinal peptide, and they are to enhancing intestines and stomach
Barrier function play an important role.
The present invention uses new resource food avenabeta glucosan, and it has β-(1,3) glycosidic bond, therefore can influence immune
Function;Beta glucan is considered as the immunologic stimulant of macrophage, T/B lymphocytes and NK cells, and oral oat β-Portugal gathers
Sugar can increase the ability of systemic immunity and intestine immunity.Avenabeta glucosan enters after human body alimentary canal, due to human intestine
Inside lack 1,4 beta-glucanase, avenabeta glucosan is not digested absorption in the small enteral of epimere, in big enteral, probiotics passes through secretion
Degraded to extracellular glycosidase, then reabsorb utilize, such avenabeta glucosan can as probiotics carbon source, choosing
Growth and the vigor of probiotics are stimulated to selecting property, so as to promote probiotics to breed.On the other hand, avenabeta glucosan is used as benefit
The fermentation substrate of raw bacterium, short chain fatty acids (SCFA) and butyric acid can be produced in colon by anaerobic bacteria catabolism.
N-3 unrighted acids in the fat that the present invention is used can block generation and the egg of arachidonic acid metabolite
The activity of white kinase c, has potential therapeutic action to inflammatory bowel disease.
Compared with prior art, the present invention has following excellent effect:
(1) modern nutriology achievement in research is combined by the present invention with Traditional Chinese medical theory, passes through the organic of various components
Combination, various functions is merged, and pass through the synergy between active ingredient, humidification effect.Match somebody with somebody by the present invention
The food that side makes can not only supplement nutrition needed for patients with inflammatory bowel, moreover it is possible to promote body condition to change using medicinal herb componentses
It is kind.
(2) the integration of drinking and medicinal herbs composition of inventive formulation food addition has growth, propagation and the mucous membrane to safeguarding intestinal mucosa
Barrier function has special role, and the water-soluble dietary fiber of addition can reduce noxious material and Inflammatory substances are entered by intestinal mucosa
Enter circulation, the new resource food of addition has the ability of increase systemic immunity and intestine immunity, in said components and albumen
Under the synergy of matter, fat etc., the erythrocyte sedimentation rate, c reactive protein and intestinal permeability of patients with inflammatory bowel can effectively improve
Symptom, actively carries out the treatment of inflammatory bowel disease symptom, with early recovery.
(3) present invention prepares vitamin using micro-capsule embedding techniques, and vitamin is embedded in wall material, can prevent dimension from giving birth to
Element is destroyed by macroelement, trace element, extends the holding time of vitamin;The present invention is prepared using micro-capsule embedding techniques
Powdered oil so that powdered oil has preferable mobility, it is easy to be well mixed with other powdered components;And use micro-capsule bag
Bury after technology, grease is embedded in wall material, so that the contact with air is avoided to strengthen inoxidizability, so as to play guarantor
The maximum effect of strong type grease;The present invention prepares integration of drinking and medicinal herbs composition and meals elite using freeze drying process, ensure that
The activity of itself of nutriment, the technique excludes more than 95%~99% moisture, enables the powder prepared after drying long-term
Preserve and never degenerate.
(4) raw material of inflammatory bowel disease tailored version clinical nutrition formula of the present invention is previously prepared in preparation process
Into 150~250 μm of powder, this make it that, when preparing finished product, each nutrition composition can be well mixed, it is ensured that in unit volume
The content of each nutrition composition is identical, while when preparing liquid type preparation, each nutrition composition can it is fully dispersed and be completely dissolved to
In solvent, prevent occurring solid precipitation in liquid, effect of finished product product has been effectively ensured.
Embodiment
The present invention provides a kind of a erythrocyte sedimentation rate, c reactive protein and intestines with improvement patient for patients with inflammatory bowel
The clinical nutrition formulation product of mucous membrane permeability symptom, includes the component of following parts by weight:Protein and amino acid 20~40
Part, 0.1~3 part of peptides, fat 5~20 parts, 20~60 parts of carbohydrate, 1~3 part of dietary fiber, macroelement 0.6~
1.2 parts, 0.01-0.06 parts of trace element, 0.05~0.25 part of vitamin, 0.2~1 part of meals elite, integration of drinking and medicinal herbs composition 0.1
0.02-0.2 parts of~6 parts, 0.1-1 parts of natural plants compound and new resource food;Wherein, protein and the amino acid institute
The good protein of offer accounts for gross protein and reaches more than 70%, and the peptides account for gross protein and reach more than 2%;The fat
Middle n-6 aliphatic acid:N-3 aliphatic acid=3~4:1;The dietary fiber be water-soluble dietary fiber, account for total formula weight 1~
3%.
With reference to embodiment, the embodiment to the present invention is further described.Following examples are only used for more
Plus technical scheme is clearly demonstrated, and can not be limited the scope of the invention with this.
Embodiment 1
Inflammatory bowel disease tailored version clinical nutrition formula of the present invention includes hydrolyzing lactoalbumin powder 11.45g, soybean water
Solve albumen 5.87g, milk powder 3.63g, dried whole-egg 0.18g, colostrum 0.09g, taurine 0.12g, soy oligosaccharides Gly-His-Lys 0.1g, sea
Foreign fish oligopeptide powder 0.1g;Perilla herb oil 0.18g, coconut oil 0.78g, soybean oil 1.27g, olive oil 0.78g, medium chain triglyceride
3.08g;Maltodextrin 51.06g, tapioca 8.63;Water-soluble dietary fiber 1.98g in dietary fiber, it includes inulin, evil spirit
At least one of taro powder, galactooligosaccharide, FOS, oligoisomaltose, soybean polyoses, cyclodextrin, resistant dextrin;Often
Calcium 0.2g, phosphorus 0.21g, potassium 0.08g, sodium 0.02g, magnesium 0.15g in secondary element;Iron 0.011g in trace element, iodine 0.00014g,
Zinc 0.007g;Vitamin A 0.0006g, beta carotene 0.000057g, vitamin D in liposoluble vitamin3 0.000001g、
Vitamin E 0.009g;Vitamin B in water soluble vitamin10.001g, vitamin B20.001g, vitamin B6 0.001g、
Vitamin B120.000002g, vitamin C 0.15g, pantothenic acid 0.003g, folic acid 0.000165g, nicotinic acid 0.0165g;Meals essence
Magnificent 0.45g, the meals elite includes millet powder, oatmeal, apple powder;Lily 0.05g, peppermint in integration of drinking and medicinal herbs composition
0.05g, radix glycyrrhizae 0.05g, Poria cocos 0.05g, raspberry 0.05g, matrimony vine 0.05g, sealwort 0.05g, jujube 0.05g;Natural plants
L-cn 0.64g in compound;Avenabeta glucosan 0.02g in new resource food.
Embodiment 2
Inflammatory bowel disease tailored version clinical nutrition formula of the present invention includes hydrolyzing lactoalbumin powder 11.45g, soybean water
Solve albumen 5.87g, milk powder 3.63g, dried whole-egg 0.18g, colostrum 0.09g, taurine 0.12g, soy oligosaccharides Gly-His-Lys 0.1g, sea
Foreign fish oligopeptide powder 0.1g;Perilla herb oil 0.18g, coconut oil 0.78g, soybean oil 1.27g, olive oil 0.78g, medium chain triglyceride
3.08g;Maltodextrin 51.06g, tapioca 8.63;Water-soluble dietary fiber 1.98g in dietary fiber, it includes inulin, evil spirit
At least one of taro powder, galactooligosaccharide, FOS, oligoisomaltose, soybean polyoses, cyclodextrin, resistant dextrin;Often
Calcium 0.2g, phosphorus 0.21g, potassium 0.08g, sodium 0.02g, magnesium 0.15g in secondary element;Iron 0.011g in trace element, iodine 0.00014g,
Zinc 0.007g;Vitamin A 0.0006g, beta carotene 0.000057g, vitamin D in liposoluble vitamin3 0.000001g、
Vitamin E 0.009g;Vitamin B in water soluble vitamin10.001g, vitamin B20.001g, vitamin B6 0.001g、
Vitamin B120.000002g, vitamin C 0.15g, pantothenic acid 0.003g, folic acid 0.000165g, nicotinic acid 0.0165g;Meals essence
Magnificent 0.45g, the meals elite includes millet powder, oatmeal, apple powder;Lily 0.1g in integration of drinking and medicinal herbs composition, peppermint 0.1g,
Radix glycyrrhizae 0.1g, Poria cocos 0.1g, raspberry 0.1g, matrimony vine 0.1g, sealwort 0.1g, jujube 0.1g;It is left-handed in natural plants compound
Carnitine 0.3g;Avenabeta glucosan 0.02g in new resource food.
Embodiment 3
Inflammatory bowel disease tailored version clinical nutrition formula of the present invention includes hydrolyzing lactoalbumin powder 11.45g, soybean water
Solve albumen 5.87g, milk powder 3.63g, dried whole-egg 0.18g, colostrum 0.09g, taurine 0.12g, soy oligosaccharides Gly-His-Lys 0.1g, sea
Foreign fish oligopeptide powder 0.1g;Perilla herb oil 0.18g, coconut oil 0.78g, soybean oil 1.27g, olive oil 0.78g, medium chain triglyceride
3.08g;Maltodextrin 51.06g, tapioca 8.63;Water-soluble dietary fiber 1.98g in dietary fiber, it includes inulin, evil spirit
At least one of taro powder, galactooligosaccharide, FOS, oligoisomaltose, soybean polyoses, cyclodextrin, resistant dextrin;Often
Calcium 0.2g, phosphorus 0.21g, potassium 0.08g, sodium 0.02g, magnesium 0.15g in secondary element;Iron 0.011g in trace element, iodine 0.00014g,
Zinc 0.007g;Vitamin A 0.0006g, beta carotene 0.000057g, vitamin D in liposoluble vitamin3 0.000001g、
Vitamin E 0.009g;Vitamin B in water soluble vitamin10.001g, vitamin B20.001g, vitamin B6 0.001g、
Vitamin B120.000002g, vitamin C 0.15g, pantothenic acid 0.003g, folic acid 0.000165g, nicotinic acid 0.0165g;Meals essence
Magnificent 0.45g, the meals elite includes millet powder, oatmeal, apple powder;Lily 0.2g in integration of drinking and medicinal herbs composition, peppermint 0.2g,
Radix glycyrrhizae 0.2g, Poria cocos 0.2g, raspberry 0.2g, matrimony vine 0.2g, sealwort 0.2g, jujube 0.2g;It is left-handed in natural plants compound
Carnitine 0.8g;Avenabeta glucosan 0.02g in new resource food.
Embodiment 4
Inflammatory bowel disease tailored version clinical nutrition formula of the present invention includes hydrolyzing lactoalbumin powder 11.45g, soybean water
Solve albumen 5.87g, milk powder 3.63g, dried whole-egg 0.18g, colostrum 0.09g, taurine 0.12g, soy oligosaccharides Gly-His-Lys 0.1g, sea
Foreign fish oligopeptide powder 0.1g;Perilla herb oil 0.18g, coconut oil 0.78g, soybean oil 1.27g, olive oil 0.78g, medium chain triglyceride
3.08g;Maltodextrin 51.06g, tapioca 8.63;Water-soluble dietary fiber 1.98g in dietary fiber, it includes inulin, evil spirit
At least one of taro powder, galactooligosaccharide, FOS, oligoisomaltose, soybean polyoses, cyclodextrin, resistant dextrin;Often
Calcium 0.2g, phosphorus 0.21g, potassium 0.08g, sodium 0.02g, magnesium 0.15g in secondary element;Iron 0.011g in trace element, iodine 0.00014g,
Zinc 0.007g;Vitamin A 0.0006g, beta carotene 0.000057g, vitamin D in liposoluble vitamin3 0.000001g、
Vitamin E 0.009g;Vitamin B in water soluble vitamin10.001g, vitamin B20.001g, vitamin B6 0.001g、
Vitamin B120.000002g, vitamin C 0.15g, pantothenic acid 0.003g, folic acid 0.000165g, nicotinic acid 0.0165g;Meals essence
Magnificent 0.45g, the meals elite includes millet powder, oatmeal, apple powder;Lily 0.1g in integration of drinking and medicinal herbs composition, peppermint 0.1g,
Radix glycyrrhizae 0.1g, Poria cocos 0.1g, raspberry 0.1g, matrimony vine 0.1g, sealwort 0.1g, jujube 0.1g;It is left-handed in natural plants compound
Carnitine 0.64g;Avenabeta glucosan 0.2g in new resource food.
Embodiment 5
The preparation method of inflammatory bowel disease tailored version clinical nutrition formula containing embodiment 1- embodiments 4 is as follows:
1) powdered oil (powder fat) is prepared:
A) the wall material aqueous solution is prepared:Take 10 grams of maltodextrin, 4 grams of soybean protein isolate, 5 grams of whole-fat milk powder, dietary fiber
2.5 grams, 5 grams of PURE WHEY, 1.5 grams of oligoisomaltose, 0.2 gram of Arabic gum, 50 milliliters of water stirs (side of having ready conditions
Heating side is stirred to 60 DEG C, and room temperature is cooled to after being kept for 30 minutes).
B) 0.1 gram (total solid concentration is 0.2%) is taken uniformly to be dissolved in (olive oil in 5.73 milliliters of greases monoglyceride
0.73 milliliter, 1.20 milliliters of soybean oil, 0.73 milliliter of coconut oil, 0.17 milliliter of perilla herb oil, 2.90 milliliters of medium chain triglyceride).
C) 0.1 gram (total solid concentration is 0.2%) is taken uniformly to be dissolved in the wall material aqueous solution Tween 80.
D) the wall material aqueous solution of the mixed plant grease and addition Over emulsfication agent Tween 80 of Over emulsfication agent monoglyceride will be added
It is sufficiently mixed.
E) addition stabilizer agar takes 0.1 gram (total solid concentration is 0.2%) to enter after mixed solution, is settled to water
Disperse 2 minutes at a high speed under 200 milliliters (total solid concentration is 25%), 20000r/min.
F) homogenization pressure is 25MPa, and homogeneous emulsion is made in homogeneous 3 times (every time 5 minutes).
G) obtained emulsion is spray-dried, EAT is 195 DEG C, leaving air temp is 80 DEG C.Collect powder
Grease (powder fat).
2) integration of drinking and medicinal herbs component powders are prepared:The raw material of predetermined weight number is crushed using pulverizer, will be crushed
Raw material be placed in container, add weight be raw material weight 3~8 times of water, carry out immersion 3~4 hours, then to soak
Carry out decocting 30~60min, filtering removes raw material, leaves and takes decoction liquor, concentrate decoction liquor, be freeze-dried, with 60~80
Mesh sieve point prepares integration of drinking and medicinal herbs component powders;
3) vitamin powder is prepared:Using the liposoluble vitamin of predetermined weight number as core, from carragheen, I
Primary glue carries out 2 emulsifying homogeneous processing, the emulsifying homogeneous time is 10~15min, is then sprayed under high pressure as wall material
It is instantaneous to dry, prepare liposoluble vitamin powder with 60~80 mesh sieves point;Using the water soluble vitamin of predetermined weight number as
Core, from maltodextrin, lipoprotein as wall material, is well mixed, and spraying is instantaneous to be dried, and is prepared with 60~80 mesh sieves point water-soluble
Property vitamin powder;
4) meals elite powder is prepared:Selection raw material, which are smashed to pieces to be placed into refrigerator, to be freezed, after freezing
Raw material be placed in sealed vacuum tank heating and dehydrate it, the vacuum degree control of the vacuum tank is in 10-
30Pa, is then heated to material temperature to carry out parsing-desiccation, the time dehydrated below the maximum temperature of its permission
For 1~2h, the time of the parsing-desiccation is 4~6h, and the raw material for drying completion was ground into 60~80 mesh sieves is prepared into
Meals elite powder.
5) by the protein and amino acid of predetermined weight, peptides, carbohydrate, dietary fiber, macroelement, micro member
Element, meals elite, natural plants compound and new resource food are prepared into the powder that particle diameter is 150~250 μm respectively;
6) by step 1)~step 5) obtained by powder sequentially add the mixers of cone-type mixer or other forms and mix
Uniformly obtained formula mixture is closed, it is standby after sterilization processing;
7) according to conventional technical means by step 6) in formula mixture be prepared into nutrient powder, nutrition emulsion, capsule,
At least one of tablet, pill or oral liquid.
In step 7) in, optionally increase appropriate food thickening agent and food additives.The food thickening agent
It is described at least one of guar gum, xanthans, locust bean gum, konjac glucomannan, pectin, carragheen, agar, gelatin, Arabic gum
Food additives are at least one of Aspartame, flavoring essence spices, brown sugar;More preferably carragheen, Arabic gum, Guar
Glue, Aspartame, flavoring essence spices.
Aforesaid operations step is both needed to carry out under the protection of inert gas, such as nitrogen, argon gas, helium etc., to prevent production
The danger of green powder blast.
Embodiment 6- inflammatory bowel diseases are tested
The present embodiment is formulated to mouse idiopathic colitis for the inflammatory bowel disease tailored version clinical nutrition that the present invention is provided
Inhibitory action.
This experiment selection interleukin-10 gene knockout (IL-10-/-) mouse 20, IL-10-/- mouse can spontaneous chronic intestines
Inflammation, its pathogenesis, characteristics of lesion are close to mankind CD.IL-10-/- mouse is randomly divided into treatment group and control group, every group 10
Only.The nutrient powder that treatment group prepares per 1~embodiment of the average daily gavage embodiment of the present invention 4, control group is per average daily gavage equal amount
Physiological saline, Therapy lasted eight weeks.
1) influence of mouse weight
Since first administration, it being determined daily and takes in appetite, claim within every 3 days 1 body weight, the final each group body weight that calculates increases
Plus, it the results are shown in Table 1.
The inflammatory bowel disease tailored version clinical nutrition of table 1 is formulated the influence to mouse weight
As can be known from the above table, nutrient formulation of the present invention can significantly improve the body weight increase of IL-10-/- mouse.
2) disease activity index is assessed
Since first administration, disease activity index scoring successively is carried out weekly, content includes having blood in stool, the prolapse of rectum, dilute
Just, horripilation, diarrhoea or with serious rectum abjection, above-mentioned each item rating is 1 point, the total score scored every time add for it and,
Score weekly once, the adduction result of the scoring of continuous eight weeks is as shown in the table.
Control group (physiological saline) | Treatment group's (nutrient powder) | |
Embodiment 1 | 15.6 | 12.0 |
Embodiment 2 | 15.8 | 11.5 |
Embodiment 3 | 15.4 | 11.2 |
Embodiment 4 | 15.5 | 11.4 |
As can be known from the above table, the disease activity index scoring for the treatment of group is lower than control group, and this shows battalion of the present invention
Foster formula can suppress the development of inflammatory bowel disease.
3) colon's pathological observation
Drawn by micro- sem observation, control group IL-10-/- mouse mucous hyperemia, erosion, it is seen that ulcer is formed, and is controlled
Treatment group symptom is lighter compared with control group, and this shows that the intestinal inflammatory journey of mouse can be reduced by eating nutrient formulation of the present invention
Degree.
Tested more than, formulation product prepared by the present invention can make it that the body weight of the mouse of inflammatory bowel disease models is bright
Aobvious rise, disease activity index scoring is significantly lower than control group, and its inflammatory symptoms shows system of the present invention compared with control group relatively light this
Standby formulation product can suppress murine chronic enteritis and develop, and have certain therapeutic action to murine chronic enteritis.
The specific embodiment of the present invention is described in detail above, but it is only used as example, and the present invention is not intended to limit
In particular embodiments described above.To those skilled in the art, it is any to the practicality carry out equivalent modifications and replace
In generation, is also all among scope of the invention.Therefore, the equalization made without departing from the spirit and scope of the invention is converted and repaiied
Change, all should be contained within the scope of the invention.
Claims (10)
1. a kind of inflammatory bowel disease tailored version clinical nutrition formula, it is characterised in that including following component:Protein and amino acid,
Peptides, fat, carbohydrate, dietary fiber, macroelement, trace element, vitamin, meals elite, integration of drinking and medicinal herbs composition,
Natural plants compound and new resource food;
Wherein, the meals elite includes millet powder, oatmeal, apple powder;
Wherein, the integration of drinking and medicinal herbs composition includes lily, peppermint, radix glycyrrhizae, Poria cocos, raspberry, matrimony vine, sealwort, jujube.
2. a kind of inflammatory bowel disease tailored version clinical nutrition formula according to claim 1, it is characterised in that also including food
Thickener and food additives, the food thickening agent are guar gum, xanthans, locust bean gum, konjac glucomannan, pectin, carragheen, fine jade
At least one of fat, gelatin, Arabic gum, the food additives be Aspartame, flavoring essence spices, brown sugar in extremely
Few one kind.
3. a kind of inflammatory bowel disease tailored version clinical nutrition formula according to claim 1, it is characterised in that the protein
Gross protein, which is accounted for, with the good protein that amino acid is provided reaches more than 70%.
4. a kind of inflammatory bowel disease tailored version clinical nutrition formula according to claim 1, it is characterised in that the peptides are accounted for
Gross protein reaches more than 2%.
5. a kind of inflammatory bowel disease tailored version clinical nutrition formula according to claim 1, it is characterised in that in the fat
N-6 aliphatic acid:N-3 aliphatic acid=3~4:1, medium chain triglyceride accounts for the 30%~50% of total lipid content.
6. a kind of inflammatory bowel disease tailored version clinical nutrition formula according to claim 1, it is characterised in that the carbon aquation
Compound is without lactose, using lactose-free formula.
7. a kind of inflammatory bowel disease tailored version clinical nutrition formula according to claim 1, it is characterised in that the meals are fine
Tie up as water-soluble dietary fiber, using low fiber prescription.
8. a kind of inflammatory bowel disease tailored version clinical nutrition formula according to claim 1, it is characterised in that the component
Parts by weight are:20~40 parts of protein and amino acid, 1~3 part of peptides, 5~20 parts of fat, 20~60 parts of carbohydrate,
1~3 part of dietary fiber, 0.6~1.2 part of macroelement, 0.01-0.06 parts of trace element, 0.05~0.25 part of vitamin, meals
0.2~1 part of elite, 0.1~6 part of integration of drinking and medicinal herbs composition, 0.1-1 parts of natural plants compound and new resource food 0.02-0.2
Part.
9. a kind of inflammatory bowel disease tailored version clinical nutrition formula according to claim 1, it is characterised in that integration of drinking and medicinal herbs into
Point in 0-1 parts of lily, 0-1 parts of peppermint, 0-1 parts of radix glycyrrhizae, 0-1 parts of Poria cocos, 0-1 parts of raspberry, 0-1 parts of matrimony vine, 0-1 parts of sealwort,
0-1 parts of jujube.
10. a kind of preparation method being formulated such as inflammatory bowel disease tailored version clinical nutrition according to any one of claims 1 to 9,
It is characterised in that it includes following steps:
Step 1: by the protein and amino acid of predetermined weight number, fat, carbohydrate, dietary fiber, macroelement,
It is 150 that trace element, vitamin, integration of drinking and medicinal herbs composition, natural plants compound and new resource food are prepared into particle diameter respectively
~250 μm of powder;
It is well mixed Step 2: powder prepared by the step one is poured into cone-type mixer successively;
Step 3: being prepared into nutrient powder, nutrition emulsion, capsule, tablet, ball using the powder being well mixed in the step 2
At least one of agent or oral liquid;
Wherein, the raw material of the integration of drinking and medicinal herbs composition is crushed, water extraction is concentrated, and concentrate progress freeze-drying is made into medicine
Eat homologous component powders;
Wherein, the vitamin and fat are handled by microencapsulation respectively is prepared into vitamin powder and fat powder;
Wherein, the meals elite is prepared into meals elite powder using freeze drying process.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710198925.5A CN106983151A (en) | 2017-03-29 | 2017-03-29 | A kind of inflammatory bowel disease tailored version clinical nutrition formula and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710198925.5A CN106983151A (en) | 2017-03-29 | 2017-03-29 | A kind of inflammatory bowel disease tailored version clinical nutrition formula and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106983151A true CN106983151A (en) | 2017-07-28 |
Family
ID=59412325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710198925.5A Pending CN106983151A (en) | 2017-03-29 | 2017-03-29 | A kind of inflammatory bowel disease tailored version clinical nutrition formula and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106983151A (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107373672A (en) * | 2017-08-23 | 2017-11-24 | 上海奥医生物医药科技有限公司 | A kind of irregular menstruation women tailored version clinical nutrition formula and preparation method thereof |
CN107440121A (en) * | 2017-08-23 | 2017-12-08 | 上海奥医生物医药科技有限公司 | A kind of Single Obesity tailored version clinical nutrition formula and preparation method thereof |
CN107440103A (en) * | 2017-08-23 | 2017-12-08 | 上海奥医生物医药科技有限公司 | A kind of respiratory disease tailored version clinical nutrition formula and preparation method thereof |
CN107440102A (en) * | 2017-08-23 | 2017-12-08 | 上海奥医生物医药科技有限公司 | A kind of climacteric women tailored version clinical nutrition formula and preparation method thereof |
CN107616490A (en) * | 2017-08-23 | 2018-01-23 | 上海奥医生物医药科技有限公司 | A kind of postoperative tailored version clinical nutrition formula of children and preparation method thereof |
CN108013453A (en) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | Children's lactose intolerance tailored version clinical nutrition formula and preparation method thereof |
CN108013454A (en) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | Gynaecological imflammation tailored version clinical nutrition formula and preparation method thereof |
CN108618129A (en) * | 2018-05-10 | 2018-10-09 | 上海奥医生物医药科技有限公司 | Sarcopenia tailored version clinical nutrition formula and preparation method thereof |
CN108651988A (en) * | 2018-05-10 | 2018-10-16 | 上海奥医生物医药科技有限公司 | Nephrosis dialysis tailored version clinical nutrition formula and preparation method thereof |
CN110432483A (en) * | 2019-07-05 | 2019-11-12 | 上海奥医高科技实业有限公司 | A kind of rheumatoid arthritis tailored version clinical nutrition formula and preparation method thereof |
CN110742267A (en) * | 2019-11-11 | 2020-02-04 | 江南大学 | Total-nutrient formula food for inflammatory bowel diseases |
CN110742266A (en) * | 2019-11-11 | 2020-02-04 | 江南大学 | Total nutrient formula food for assisting in regulating intestinal immunity function |
CN111109605A (en) * | 2020-01-21 | 2020-05-08 | 山东省农业科学院农产品研究所 | Special emulsion for relieving enteritis symptom and preparation method thereof |
CN113615831A (en) * | 2021-08-31 | 2021-11-09 | 西安交通大学医学院第一附属医院 | Clinical nutrition composition for promoting mucosa repair of ulcerative colitis and preparation method thereof |
CN115697084A (en) * | 2020-04-01 | 2023-02-03 | 沃尔夫森医疗中心 | Ulcerative colitis diet, formulations, products, and methods thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104839695A (en) * | 2015-04-23 | 2015-08-19 | 劲膳美生物科技股份有限公司 | Inflammatory bowel disease non-total nutrient formula food |
CN106490605A (en) * | 2016-12-23 | 2017-03-15 | 上海奥医生物医药科技有限公司 | A kind of hypertension of pregnancy tailored version clinical nutrition formula and preparation method thereof |
-
2017
- 2017-03-29 CN CN201710198925.5A patent/CN106983151A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104839695A (en) * | 2015-04-23 | 2015-08-19 | 劲膳美生物科技股份有限公司 | Inflammatory bowel disease non-total nutrient formula food |
CN106490605A (en) * | 2016-12-23 | 2017-03-15 | 上海奥医生物医药科技有限公司 | A kind of hypertension of pregnancy tailored version clinical nutrition formula and preparation method thereof |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107373672A (en) * | 2017-08-23 | 2017-11-24 | 上海奥医生物医药科技有限公司 | A kind of irregular menstruation women tailored version clinical nutrition formula and preparation method thereof |
CN107440121A (en) * | 2017-08-23 | 2017-12-08 | 上海奥医生物医药科技有限公司 | A kind of Single Obesity tailored version clinical nutrition formula and preparation method thereof |
CN107440103A (en) * | 2017-08-23 | 2017-12-08 | 上海奥医生物医药科技有限公司 | A kind of respiratory disease tailored version clinical nutrition formula and preparation method thereof |
CN107440102A (en) * | 2017-08-23 | 2017-12-08 | 上海奥医生物医药科技有限公司 | A kind of climacteric women tailored version clinical nutrition formula and preparation method thereof |
CN107616490A (en) * | 2017-08-23 | 2018-01-23 | 上海奥医生物医药科技有限公司 | A kind of postoperative tailored version clinical nutrition formula of children and preparation method thereof |
CN108013453A (en) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | Children's lactose intolerance tailored version clinical nutrition formula and preparation method thereof |
CN108013454A (en) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | Gynaecological imflammation tailored version clinical nutrition formula and preparation method thereof |
CN108651988A (en) * | 2018-05-10 | 2018-10-16 | 上海奥医生物医药科技有限公司 | Nephrosis dialysis tailored version clinical nutrition formula and preparation method thereof |
CN108618129A (en) * | 2018-05-10 | 2018-10-09 | 上海奥医生物医药科技有限公司 | Sarcopenia tailored version clinical nutrition formula and preparation method thereof |
CN110432483A (en) * | 2019-07-05 | 2019-11-12 | 上海奥医高科技实业有限公司 | A kind of rheumatoid arthritis tailored version clinical nutrition formula and preparation method thereof |
CN110742267A (en) * | 2019-11-11 | 2020-02-04 | 江南大学 | Total-nutrient formula food for inflammatory bowel diseases |
CN110742266A (en) * | 2019-11-11 | 2020-02-04 | 江南大学 | Total nutrient formula food for assisting in regulating intestinal immunity function |
CN110742267B (en) * | 2019-11-11 | 2022-09-27 | 江南大学 | Total-nutrient formula food for inflammatory bowel diseases |
CN110742266B (en) * | 2019-11-11 | 2022-11-01 | 江南大学 | Total nutrient formula food for assisting in regulating intestinal immunity function |
CN111109605A (en) * | 2020-01-21 | 2020-05-08 | 山东省农业科学院农产品研究所 | Special emulsion for relieving enteritis symptom and preparation method thereof |
CN115697084A (en) * | 2020-04-01 | 2023-02-03 | 沃尔夫森医疗中心 | Ulcerative colitis diet, formulations, products, and methods thereof |
CN113615831A (en) * | 2021-08-31 | 2021-11-09 | 西安交通大学医学院第一附属医院 | Clinical nutrition composition for promoting mucosa repair of ulcerative colitis and preparation method thereof |
CN113615831B (en) * | 2021-08-31 | 2023-09-01 | 西安交通大学医学院第一附属医院 | Clinical nutrition composition for promoting repair of ulcerative colitis mucous membrane and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106983151A (en) | A kind of inflammatory bowel disease tailored version clinical nutrition formula and preparation method thereof | |
CN106983136A (en) | A kind of puerperium conditioning tailored version clinical nutrition formula and preparation method thereof | |
CN107319525A (en) | One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof | |
CN109645320A (en) | A kind of light jejunitas full nutrient formulation can brew instant stick and preparation method thereof | |
CN106962912A (en) | A kind of hepatopathy tailored version clinical nutrition formula and preparation method thereof | |
CN108618129A (en) | Sarcopenia tailored version clinical nutrition formula and preparation method thereof | |
CN106858620A (en) | A kind of anaemia tailored version clinical nutrition formula and preparation method thereof | |
CN106616615A (en) | Clinical nutrient formula special for tumor and preparation method of clinical nutrient formula | |
CN104171903A (en) | Nourishing life-prolonging noodles | |
CN106819793A (en) | A kind of instant class nutritional meal replacing food of quinoa | |
KR101834640B1 (en) | Functionality porridge for old-age dog and manufacturing method thereby | |
CN107319524A (en) | A kind of nephrosis tailored version clinical nutrition formula and preparation method thereof | |
CN106942748A (en) | A kind of female acyesis tailored version clinical nutrition formula and preparation method thereof | |
CN107440120A (en) | A kind of children's monophagia and anorexia tailored version clinical nutrition formula particular about food and preparation method thereof | |
CN108651988A (en) | Nephrosis dialysis tailored version clinical nutrition formula and preparation method thereof | |
CN104187611A (en) | Total nutrient formula food for gastrointestinal malabsorption | |
CN108719984B (en) | Meal replacement nutrition bar for gout population and preparation method thereof | |
CN110074397A (en) | A kind of upgrowth and development of children tailored version clinical nutrition formula and preparation method thereof | |
CN107616490A (en) | A kind of postoperative tailored version clinical nutrition formula of children and preparation method thereof | |
CN104855985A (en) | Non-complete-nutrition formula food for high uric acid | |
CN107440121A (en) | A kind of Single Obesity tailored version clinical nutrition formula and preparation method thereof | |
CN106578093A (en) | Wound, infection, operation and other stress state special-purpose clinical nutrition formula and preparation method thereof | |
CN108703365A (en) | Protein allergy tailored version clinical nutrition formula and preparation method thereof | |
CN106418501A (en) | Healthcare food with weight reducing function | |
CN102283342B (en) | Functional total-nutrient liquid food for space flight and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170728 |